Top Prostate Cancer News of 2016

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Experts weigh in on the practical applications of PSMA PET imaging

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.